Citi believes a series of near-term triggers in the US market could support further upside for the stock. These include the potential approval of generic Flovent (gFlovent), the launch of generic Ventolin (gVentolin), and Cipla’s growing presence in the Nintedanib market, where its market share is approaching 50%.
